Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn
Andrade, Susan E. ; McPhillips, Heather ; Loren, David ; Raebel, Marsha A. ; Lane, Kimberly ; Livingston, James ; Boudreau, Denise M. ; Smith, David H. ; Davis, Robert L. ; Willy, Mary E. ... show 1 more
Citations
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Keywords
Adolescent
Adult
Antidepressive Agents
Databases, Factual
Female
Humans
Infant, Newborn
Maternal-Fetal Exchange
Middle Aged
Persistent Fetal Circulation Syndrome
Pregnancy
Pregnancy Trimester, Third
*Prenatal Exposure Delayed Effects
Prevalence
Retrospective Studies
Risk Factors
Serotonin Uptake Inhibitors
Health Services Research
Primary Care
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
PURPOSE: To determine the prevalence of persistent pulmonary hypertension of the newborn (PPHN) among infants whose mothers were exposed to antidepressants in the third trimester of pregnancy compared to the prevalence among infants whose mothers were not exposed to antidepressants in the third trimester.
METHODS: A retrospective study was conducted using the automated databases of four health plans participating in the HMO Research Network Center for Education and Research on Therapeutics. Women who delivered an infant in a hospital from 1 January 1996 through 31 December 2000 were identified. The administrative databases were used to identify full-term infants whose mothers received an antidepressant during the third trimester of pregnancy and unexposed infants whose mothers did not receive an antidepressant during the third trimester. Hospitalization data were used to identify diagnoses or procedure codes potentially indicative of PPHN.
RESULTS: Among 1104 infants exposed to antidepressants in the third trimester and a matched sample of 1104 unexposed infants, five infants were classified by the expert reviewers as having PPHN. Among those infants whose mothers were exposed to selective serotonin reuptake inhibitors (SSRIs) in the third trimester, the prevalence of PPHN was 2.14 per 1000 (95% confidence interval (CI) 0.26, 7.74), while the prevalence among infants whose mothers were not exposed was 2.72 per 1000 (95%CI 0.56, 7.93).
CONCLUSIONS: We did not find an association between SSRI use in late pregnancy and PPHN. Limitations of the present study, including the small number of confirmed cases, suggest further research in this area may be warranted.
Source
Pharmacoepidemiol Drug Saf. 2009 Mar;18(3):246-52. Link to article on publisher's site